Form4insider filings, from the source

SEC Form 4 · accession 0001676170-26-000016

Maze Therapeutics, Inc. · MAZE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jason V Coloma
Officer — Chief Executive Officer · Director
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001842295

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2,F3Aug 3, 2026S2,439$26.7145D20,898IThe Coloma 2021 Irrevocable Trust
Common StockF4,F3Aug 3, 2026S154$27.094D20,744IThe Coloma 2021 Irrevocable Trust
Common StockF5,F6Aug 3, 2026S30,304$26.714D256,867IColoma Family Trust
Common StockF7,F6Aug 3, 2026S1,604$27.0853D255,263IColoma Family Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses